Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Retained Earnings (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Retained Earnings for 7 consecutive years, with -$1.0 billion as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 35.36% to -$1.0 billion in Q4 2025 year-over-year; TTM through Nov 2025 was -$1.0 billion, a 35.36% decrease, with the full-year FY2025 number at -$1.0 billion, down 35.36% from a year prior.
  • Retained Earnings was -$1.0 billion for Q4 2025 at Nurix Therapeutics, down from -$925.0 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $226000.0 in Q1 2025 to a low of -$1.0 billion in Q4 2025.
  • A 5-year average of -$307.1 million and a median of -$195.7 million in 2021 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: crashed 600747.46% in 2022, then soared 164.57% in 2025.
  • Nurix Therapeutics' Retained Earnings stood at -$608000.0 in 2021, then plummeted by 610.36% to -$4.3 million in 2022, then soared by 84.83% to -$655000.0 in 2023, then crashed by 112689.16% to -$738.8 million in 2024, then crashed by 35.36% to -$1.0 billion in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Retained Earnings are -$1.0 billion (Q4 2025), -$925.0 million (Q3 2025), and -$20000.0 (Q2 2025).